Physician profile
Kenneth Lin
NPI 1154685378
$2,534.22
in general payments reported to CMS, 2019-2025
21 companies · $76.59 in 2025
The $76.59 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $892 · 2023: $1,166 · 2024: $275 · 2025: $76.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.69 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $314.78 | 2022-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $304.02 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $214.86 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $183.60 | 2023 | |
| Neurocrine Biosciences, INC. | $152.36 | 2022-2023 | Ingrezza |
| Alkermes, INC. | $148.47 | 2022-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $119.47 | 2022-2024 | Trintellix |
| Corium, LLC | $106.10 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $97.82 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $95.58 | 2022-2024 | Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $83.11 | 2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $80.17 | 2022 | |
| Almatica Pharma LLC | $72.19 | 2022-2024 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $68.20 | 2023 | Auvelity, Sunosi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $63.99 | 2022 | |
| Bausch Health US, LLC | $37.13 | 2023 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $28.80 | 2024 | Qelbree |
| Noven Therapeutics, LLC | $17.27 | 2023 | Xelstrym |
| Bioxcel Therapeutics, INC. | $14.93 | 2023 | Igalmi |
| Tris Pharma INC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.